# Pizarra — PT-pseudo_c9d31197c533 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c9d31197c533
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 10.92 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.26 ng/mL²
  - PSA velocity: 1.16 ng/mL/yr
  - Prior PSA: 10.0 ng/mL
  - Prostate volume: 42.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8727174 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: valsartan, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 10.92 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 42 mL. DRE nodus. csPCa 0.87.

Vitals: weight 73 kg, height 172 cm, BMI 24.7, BP 125/92 mmHg, HR 75 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation and confirmation of Gleason 4+3 carcinoma on prior biopsy bucket "Positive" warrant clinical reassessment.

History: A 61-year-old retired bank clerk entered the diagnostic pathway in late 2023 due to elevated PSA levels. He is a non-smoker with a background of hypertension treated by valsartan and lisinopril, plus osteoarthritis managed with paracetamol PRN. Divorced, he resides in an assisted-living facility and enjoys tennis twice weekly, averaging 22 units of alcohol each week. With his daughter handling correspondence under consent, he recently completed baseline memory screening and a sleep clinic assessment for suspected obstructive sleep apnoea. A prior 12-core biopsy confirmed Gleason 4+3 disease. He experiences chronic lower urinary tract symptoms yielding an IPSS of 20/35, yet denies urinary retention, haematuria, unexplained weight loss, or bone pain. His overall condition remains stable.

Physical examination: DRE — texture: moderately enlarged gland with a firm, discrete nodule palpable in the left peripheral zone; remainder symmetrically smooth without induration. General examination shows stable vital signs, unremarkable systemic findings, and no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Divorced; Lives in assisted-living facility.
Next of kin: Nephew.

Lifestyle: alcohol 22 units / week; exercise Tennis 2x/week; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Memory clinic — baseline screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.38 +/- 0.19   (95% CI 0.07-0.78)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=10.92, age=61.0, psad=0.26, dre_ord=1.0, vol=42.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.16 ng/mL/yr), the specific PI-RADS 5 score in conjunction with the prior positive biopsy, or the clinical context of severe LUTS (IPSS 20/35) and the specific DRE finding ("Nodus").

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.38 +/- 0.19), indicating high uncertainty. This uncertainty could stem from the conflict between the high csPCa probability (0.8727174) and the PI-RADS 5 score, or the prior positive biopsy status. The prior cannot account for the clinical significance of the rising PSA velocity (1.16 ng/mL/yr) or the specific clinical symptoms (IPSS 20/35) which might override the statistical prediction.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or suspicious features beyond the PI-RADS 5, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> If these notes detail the clinical correlation between the prior positive biopsy and current symptoms, it would refine the clinical context.
  <document> laboratory results (full panel) -> To check for any other relevant laboratory markers that might influence the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_c9d31197c533", "radiology_report": "Amsterdam UMC (location AMC) | 15 January 2025 | Multiparametric MRI Prostate\n\nClinical Indication:\nRe-evaluation for rising PSA (10.92 ng/mL) and prior positive biopsy. Clinical suspicion for clinically significant prostate cancer.\n\nFINDINGS:\nProstate volume measures 42.0 mL. A focal lesion is identified in the left peripheral zone, extending from the base to the mid gland, measuring approximately 18 x 14 x 12 mm. The lesion demonstrates marked hypointensity on T2-weighted images, restricted diffusion on DWI with corresponding low ADC values, and early focal enhancement on dynamic contrast-enhanced sequences. No extraprostatic extension or seminal vesicle invasion is identified.\n\nIMPRESSION:\n- PI-RADS 5 lesion in the left peripheral zone.\n- Prostate volume 42.0 mL; PSA density 0.26 ng/mL/mL.\n- csPCa predicted probability 0.8727174."}

  **psa_trend**
  {"case_id": "PT-pseudo_c9d31197c533", "psa_trend": [{"date": "Dec 2023", "val": 4.5}, {"date": "Mar 2024", "val": 5.6}, {"date": "Jul 2024", "val": 7.0}, {"date": "Oct 2024", "val": 8.7}, {"date": "Feb 2025", "val": 10.92}]}

  **previous_notes**
  {"case_id": "PT-pseudo_c9d31197c533", "previous_notes": [{"date": "07 Jun 2024", "author": "Dr. R. Visser (GP)", "text": "Clinical review addressed a fluctuating PSA trajectory, recording 9.3 ng/mL in March followed by 8.6 ng/mL in July 2024. Earlier tissue sampling established Gleason 4+3 disease. Hypertension remains well-managed through valsartan and lisinopril therapy."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_c9d31197c533", "laboratory_results": [{"name": "PSA", "val": "10.9 ng/mL", "date": "09 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.10 ng/mL", "date": "09 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "10%", "date": "09 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "13.2 g/dL", "date": "09 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.1 x10^9/L", "date": "09 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "171 x10^9/L", "date": "09 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "97 umol/L", "date": "09 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "9.3 nmol/L", "date": "09 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "81 U/L", "date": "09 Jan 2025", "flag": ""}, {"name": "LDH", "val": "203 U/L", "date": "09 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "6.3 %", "date": "09 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 5 lesion in the left peripheral zone
  - PSA velocity of 1.16 ng/mL/yr
  - csPCa predicted probability of 0.8727174

  AGAINST sampling this patient now:
  - Prior biopsy was Positive (None · Negative · ASAP/HGPIN · Positive)

WHERE THIS LEANS
  The retrieved evidence strongly argues for further investigation due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which aligns with the LLM-1-GAP-ANALYST's concerns about the statistical prior. This leans towards recommending a biopsy to confirm the extent of the disease suggested by the imaging.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient presents with a high-risk PI-RADS 5 lesion and a concerning PSA velocity of 1.16 ng/mL/yr, which strongly argues for further tissue confirmation. This decision is made despite the prior positive biopsy, as the new high-risk imaging finding and rising PSA trajectory necessitate re-evaluation of management. The PI-RADS 5 score and the PSA velocity were decisive factors in this recommendation.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
